{
    "clinical_study": {
        "@rank": "100660", 
        "arm_group": [
            {
                "arm_group_label": "Epoetin alfa", 
                "arm_group_type": "Experimental", 
                "description": "Epoetin alfa Test - Blau"
            }, 
            {
                "arm_group_label": "Eprex", 
                "arm_group_type": "Active Comparator", 
                "description": "Epoetin alfa Comparator - JANSSEN-CILAG"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the clinical efficacy and immunogenicity of the drug test Eritromax \u00ae - (rHuEPO\n      Blau) compared to drug Eprex \u00ae (Janssen-Cilag rHuEPO) in the treatment of patients who have\n      anemia secondary to chronic kidney disease (CKD), during the correction through assessing\n      the change in hemoglobin levels."
        }, 
        "brief_title": "Evaluation Of Clinical Efficacy And Immunogenicity Of Eritromax\u00ae Produced By Lab Blau Pharmaceutical S / A. Compared To The Product Eprex\u00ae, Produced By The Laboratory Janssen-Cilag, In Patients With Anemia Secondary To Chronic Kidney Disease", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Anemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Data will be assessed secondary efficacy of the drug against the test drug comparison by\n      evaluating:\n\n        -  Maintenance of hemoglobin levels (baseline vs. end of treatment) during maintenance\n           phase;\n\n        -  Dose of EPO necessary during the repair and maintenance;\n\n        -  Need for transfusion;\n\n        -  Safety study drugs by type, frequency and intensity of adverse events during the 12\n           months of follow up.\n\n      objectives exploratory\n\n        -  evaluate the immunogenicity of drugs through the quantification of anti-erythropoietin\n           every six months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        a. Confirm voluntary participation and agree to all the purposes of the study by signing\n        and dating the IC in two ways; b. Male or female, regardless of race or social class; c.\n        Age between 18 and 60 years; d. Bearer dialysis-dependent CKD (hemodialysis and peritoneal\n        dialysis *); and. Present clinical diagnosis of anemia, characterized in hemoglobin levels\n        <10g/dL before the start of the study; f. Adequate dialysis: Kt / V \u2265 1.2 for hemodialysis\n        patients and \u2265 1.8 for patients on peritoneal dialysis (based on the calculation of\n        Daugirdas II); g. Display adequate iron stores (TSAT> 20% and serum ferritin> 100ng/ml)\n        prior to initiation of treatment with erythropoietin\n\n        Exclusion Criteria:\n\n          1. Participation in clinical trials in the 12 months preceding the survey;\n\n          2. Patients with uncontrolled hypertension, with above average 180/100mmHg and requiring\n             hospitalization in the last 6 months;\n\n          3. Presence of other causes of anemia than CRD, such as bleeding, hemolysis, pernicious\n             anemia and hemoglobinopathies;\n\n          4. Patients who present changes or clinical abnormalities, qualified as interfering\n             changes, such as severe hyperparathyroidism (iPTH> 1000 pg / mL), severe congestive\n             heart failure (NYHA Class IV), acute myocardial infarction within the last 3 months,\n             or active neoplasia in follow-up, severe liver disease, active infection (leukocyte\n             changes), history of aluminum toxicity or scheduled surgery, pregnancy or lactation;\n             and. Patients who have a known hypersensitivity to any component of the formulation\n             and to products derived from mammalian cells;\n\n        f. Prior therapies with erythropoietin for less than 3 months; g. Realization transfusion\n        for less than 3 months; h. Any situation at the discretion of the Principal Investigator\n        interfere with study data."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695759", 
            "org_study_id": "EPOBLA1011", 
            "secondary_id": "Emenda 01 13/08/2012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Epoetin alfa", 
                "Eprex"
            ], 
            "description": "The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.", 
            "intervention_name": "Epoetin Alfa", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anemia Secondary", 
            "Chronic Kidney Disease"
        ], 
        "lastchanged_date": "September 27, 2012", 
        "location": [
            {
                "contact": {
                    "email": "mcriella@pro-renal.org.br", 
                    "last_name": "Miguel Carlos Riella", 
                    "phone": "(41) 3027-5442"
                }, 
                "facility": {
                    "address": {
                        "city": "Curitiba", 
                        "country": "Brazil", 
                        "state": "Parana"
                    }, 
                    "name": "Instituto Scribner de Ensino, Pesquisa, Ci\u00eancia e Tecnologia"
                }, 
                "investigator": {
                    "last_name": "Miguel Carlos Riella", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "pesquisanefropucrs@hotmail.com", 
                    "last_name": "Domingos Ot\u00e1vio Lorenzoni D'Avila", 
                    "phone": "(51) 3320-3479"
                }, 
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "Rio Grande do Sul"
                    }, 
                    "name": "Uni\u00e3o Brasileira de Educa\u00e7\u00e3o e Assist\u00eancia Hospital S\u00e3o Lucas da PUCRS"
                }, 
                "investigator": {
                    "last_name": "Domingos Ot\u00e1vio Lorenzoni D'Avila", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ronivantxsantacasa@yahoo.com.br", 
                    "last_name": "Jo\u00e3o Carlos Goldani", 
                    "phone": "(51) 3214-8640"
                }, 
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "Rio Grande do Sul"
                    }, 
                    "name": "Irmandade da Santa Casa de Miseric\u00f3rdia de Porto Alegre"
                }, 
                "investigator": {
                    "last_name": "Jo\u00e3o Carlos Goldani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cemec.abc@terra.com.br", 
                    "last_name": "Jo\u00e3o Batista Douverny, physician", 
                    "phone": "(11) 4930-4243"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Bernardo do Campo", 
                        "country": "Brazil", 
                        "state": "S\u00e3o Paulo"
                    }, 
                    "name": "Hospital de Ensino Padre Anchieta"
                }, 
                "investigator": {
                    "last_name": "Jo\u00e3o Batista Douverny", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dialisefor@uol.com.br", 
                    "last_name": "Maria Eug\u00eania Canziani", 
                    "phone": "(11) 5904-8499"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Funda\u00e7\u00e3o Oswaldo Cruz (Hospital do Rim e Hipertens\u00e3o)"
                }, 
                "investigator": {
                    "last_name": "Maria Eug\u00eania Canziani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "irenenor@usp.br", 
                    "last_name": "Irene de Lourdes Noronha", 
                    "phone": "(11) 2359-2703"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia S\u00e3o Paulo (Hospital Benefic\u00eancia Portuguesa)"
                }, 
                "investigator": {
                    "last_name": "Irene de Lourdes Noronha", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "alexandre@lalclinica.com.br", 
            "last_name": "Alexandre Frederico, physician", 
            "phone": "(19) 38716399"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of serum Hb (baseline vs end of treatment (EOIT)", 
            "safety_issue": "Yes", 
            "time_frame": "until 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695759"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Maintenance of Hb levels", 
            "safety_issue": "Yes", 
            "time_frame": "until the end of 12 months"
        }, 
        "source": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}